Abstract: DNA probes for diagnosing infectious diseases involving Escherichia coli, Klebsielkli pneunmoniae or Enterobacter cloacae and methods of using such probes are provided.

Abstract: The invention provides a probe useful for rapidly detecting and identifying fungi causative of infectious diseases by digesting completely a DNA extracted from a fungus, e.g., Candida albicans, with EcoRI, inserting the same into an appropriate cloning vector, and selecting a probe containing DNA fragments unique to each fungus. The invention also provides a standard sequence suitable for making reference to a genomic DNA contained in a clinical specimen by elucidating the base sequence of the probe thus selected.

Abstract: The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-1 strains MN and III.sub.B as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC HB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hybridoma cell line ATCC HB 10726 are specifically disclosed.

Abstract: The present invention provides a monoclonal antibody, designated NM03, which specifically binds HIV-1 gp 120.

Abstract: The present invention provides a method for delivering ionizing radiation to specific tissues, resulting in the activation of a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. The radiation source may be will generally be in the form of a radionuclide, capable of gamma or beta emissions. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.

Abstract: The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-1 strains MN and III.sub.B as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC HB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hybridoma cell line ATCC HB 10726 are specifically disclosed.

Abstract: The invention provides methods and materials for the detection and identification of biotin-containing bacteria and/or yeast in phagocyte-containing samples obtained from patients.

Abstract: Disclosed are compositions comprising caramel that have anti-plant pathogen activity. Methods of treatment of higher plants with the compositions to inhibit both the infection of plants by pathogens and the multiplication of pathogens in infected plants are also provided. Compositions according to the present invention are particularly suited for use against plant viruses such as cucumber mosaic virus.

Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passave vaccination procedures.

Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.

Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 anti-bodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.

Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.